Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Industry Today.
Press releases published on June 23, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
GlobeNewswire
·
June 23, 2025
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial reduction in T cell activity highlights the potential …
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
GlobeNewswire
·
June 23, 2025
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 …
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
GlobeNewswire
·
June 23, 2025
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule …
Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025
GlobeNewswire
·
June 23, 2025
Patients treated with CX11 (also designated as VCT220) achieved a 9.7% and 9.4% decrease in body weight from baseline after 16 weeks (p≤0.001) in the 160 mg fast and slow titration cohorts, respectively. Results suggest a favorable tolerability profile, …
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
GlobeNewswire
·
June 23, 2025
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that Annika …
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
GlobeNewswire
·
June 23, 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment …
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
GlobeNewswire
·
June 23, 2025
Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
GlobeNewswire
·
June 23, 2025
A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“ …
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
GlobeNewswire
·
June 23, 2025
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the …
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
GlobeNewswire
·
June 23, 2025
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce …
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
GlobeNewswire
·
June 23, 2025
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: …
CorMedix inc. Announces Customer Implementation
GlobeNewswire
·
June 23, 2025
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update …
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewswire
·
June 23, 2025
Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseases OrthoCellix is …
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label …
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
GlobeNewswire
·
June 23, 2025
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating …
OXB completes acquisition of remaining stake in US subsidiary
GlobeNewswire
·
June 23, 2025
OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a …
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
GlobeNewswire
·
June 23, 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed …
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
June 23, 2025
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor …
New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
GlobeNewswire
·
June 23, 2025
BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102,166 GLP-1 …